US EditionXenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
Xenon Pharmaceuticals announces Phase 3 topline results for azetukalner, targeting focal onset seizures with a novel KV7 potassium channel opener.
- On Monday, March 9, 2026, Xenon Pharmaceuticals Inc. will announce topline Phase 3 X-TOLE2 results for azetukalner in patients with focal onset seizures.
- The company is a neuroscience-focused biopharmaceutical firm, Nasdaq: XENE, dedicated to drug discovery and development, advancing early-stage KV7 and NaV1.7 programs.
- A webcast and phone conference is set for 8:00 am ET , with pre-registration available and toll-free and international dial-in lines provided.
- The GlobeNewswire distribution and dateline indicate the press release was issued from VANCOUVER, British Columbia and BOSTON on March 08, 2026, providing immediate access to the topline announcement.
- Azetukalner's KV7 mechanism positions it within Xenon's channel-modulator strategy, as topline Phase 3 results will inform clinical development direction for KV7 and related programs.
16 Articles
16 Articles
The Toronto Star
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq: XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from…
Xenon to Announce Topline Results from Phase 3 X-TOLE2 Study of Azetukalner in Focal Onset Seizures on Monday, March 9, 2026 - Xenon Pharmaceuticals (NASDAQ:XENE)
VANCOUVER, British Columbia and BOSTON, March 08, 2026 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (NASDAQ:XENE), a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development and commercialization of life-changing therapeutics for patients in need, will announce topline data from the Phase 3 X-TOLE2 study of azetukalner, a novel, potent KV7 potassium channel opener, in patients with focal onset seizures (…
Xenon gets Phase 3 win with epilepsy drug, fueling blockbuster hopes for its first launch
Xenon Pharmaceuticals' lead drug greatly reduced the frequency of seizures in a Phase 3 epilepsy study, supporting the company's plans to file for FDA approval in the third quarter. The drug, azetukalner, would be Xenon' ...
How effective is Xenon's seizure drug?
Late stage trial shows significant seizure reduction A phase 3 study released by the company reported that patients treated with the new therapy experienced a meaningful drop in the frequency of a common form of seizures compared with those given a placebo. Trial participants on the experimental…
Coverage Details
Bias Distribution
- 67% of the sources lean Left
Factuality
To view factuality data please Upgrade to Premium
